# US 2004/0082018 A1 · Methods for using osteocalcin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082018 A1
- Document ID: US20040082018A1
- Status: Published application
- Kind: A1
- Application number: 10/283,656
- Filed: 2002-10-29
- Published: 2004-04-29
- Earliest claimed: 2002-10-29
- Assignees: Athersys, Inc.
- Inventors: George Mbella Ekema; Robert W. Mays; Kurt R. Brunden
- Web page: https://patentgrep.com/patent/US20040082018A1

## CPC

- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 33/5044: {involving specific cell types}
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2500/10: involving cells
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods for using osteocalcin. The invention also relates to methods for using polynucleotides encoding osteocalcin. The invention relates to methods using the osteocalcin polypeptides and polynucleotides as a target for diagnosis and treatment osteocalcin related conditions. The invention further relates to drug-screening methods using the osteocalcin polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the osteocalcin polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the osteocalcin polypeptides and polynucleotides as a target. The invention further related to methods of treating a subject suffering from an osteocalcin mediated condition.

## Claims

### Claim 1

A method for identifying an agent that modulates the level or activity of osteocalcin in a cell, wherein osteocalcin is selected from the group consisting of:
(a) The amino acid sequence shown in SEQ ID NO:2;
(b) The amino acid sequence of an allelic variant of the amino acid sequence shown in SEQ ID NO: 2;
(c) The amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO: 2, wherein the sequence variant is encoded by a nucleic acid molecule hybridizing to the nucleic acid molecule shown in SEQ ID NO:1 under stringent conditions;
(d) A fragment of the amino acid sequence shown in SEQ ID NO:2, wherein the fragment comprises at least 10 contiguous amino acids;
(e) The amino acid sequence of an epitope bearing region of anyone of the polypeptides of (a)-(d);
said method comprising: contacting said agent with a cell capable of expressing said osteocalcin such that said osteocalcin level or activity can be modulated in said cell by said agent and measuring said osteocalcin level or activity.

### Claim 2 (depends on 1)

The method of claim 1 wherein said cell is selected from the group consisting of osteoblast, ondontoblast, bone, kidney, prostate, salivary glands, testis, thymus, brain, trachea and thyroid cell.

### Claim 3 (depends on 2)

The method of claim 2 wherein said cell is a recombinant cell expressing CaR2.

### Claim 4 (depends on 2)

The method of claim 2, wherein said cell is derived from a subject having a condition selected from the group consisting of extracellular calcium concentration, metabolic disorders associated with CaR2 or osteocalcin, osteoporosis, sperm motility and viability, regulation of calcium flux in the kidneys, kidney stone formation, regulation of calcium flux in the prostate, promotion of osteoblast proliferation, metastasis of cancer, and cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein activity is measured by the ability of osteocalcin to bind to or activate CaR2.

### Claim 6 (depends on 6)

The method of claim 6, wherein activation of CaR2 is determined by an assay for CaR2 activity.

### Claim 7 (depends on 1)

The method of claim 1 wherein said agent increases interaction between said osteocalcin and a target molecule for said osteocalcin, said method comprising: combining said osteocalcin with said agent under conditions that allow said osteocalcin to interact with said target molecule; and detecting the formation of a complex between said osteocalcin and said target molecule or activity of said osteocalcin as a result of interaction of said osteocalcin with said target molecule.

### Claim 8 (depends on 1)

The method of claim 1 wherein said agent decreases interaction between said osteocalcin and a target molecule for said osteocalcin, said method comprising: combining said osteocalcin with said agent under conditions that allow said osteocalcin to interact with said target molecule; and detecting the formation of a complex between said osteocalcin and said target molecule or activity of said osteocalcin as a result of interaction of said osteocalcin with said target molecule.

### Claim 9 (depends on 1)

The method of claim 1 wherein said agent is selected from the group consisting of a peptide; antibody; organic molecule; and inorganic molecule.

### Claim 10

A method for identifying an agent that modulates the level or activity of a nucleic acid molecule in a cell, wherein said nucleic acid molecule has a nucleic acid sequence selected from the group consisting of:
(a) The nucleotide sequence shown in SEQ ID NO:1;
(b) A nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 2;
(c) A nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), or (c).
(d) A nucleotide sequence encoding an amino acid sequence or a sequence variant of the amino acid sequence shown in SEQ ID NO: 2 that hybridizes to the nucleotide sequence shown in SEQ ID NO:1 under stringent conditions;
(e) A nucleotide sequence encoding a fragment of the amino acid sequence shown in SEQ ID NO:2, wherein the fragment comprises at least 10 contiguous amino acids;
said method comprising contacting said agent with a cell capable of expressing said nucleic acid molecule such that said nucleic acid molecule level or activity can be modulated in said cell by said agent and measuring said nucleic acid molecule level or activity.

### Claim 11 (depends on 10)

The method of claim 10 wherein said cell is selected from the group consisting of osteoblast, ondontoblast, bone, kidney, prostate, salivary glands, testis, thymus, brain, trachea and thyroid cell.

### Claim 12 (depends on 11)

The method of claim 11 wherein said cell is a recombinant cell expressing CaR2.

### Claim 13 (depends on 11)

The method of claim 11, wherein said cell is derived from a subject having a condition selected from the group consisting of extracellular calcium concentration, metabolic disorders associated with CaR2 or osteocalcin, osteoporosis, sperm motility and viability, regulation of calcium flux in the kidneys, kidney stone formation, regulation of calcium flux in the prostate, promotion of osteoblast proliferation, metastasis of cancer, and cancer.

### Claim 14

A method of treating an individual having an osteocalcin related disorder said method comprising:
administering to said individual an effective amount of a osteocalcin modulator
such that said individual is treated.

### Claim 15

A method of treating an individual having a CaR2 associated disorder said method comprising:
administering to said individual an effective amount of a osteocalcin modulator
such that said individual is treated.

### Claim 16

A method of modulating the activity of osteocalcin comprising
administering to a subject a compound that interferes with the osteocalcin-CaR2 interaction
thereby modulating the activity of osteocalcin in a subject.
